01 May 2018
Our Client Briefing on Biotech Listings focusses on the regime for pre-revenue biotech companies
The Stock Exchange of Hong Kong Limited (the Exchange) has concluded its consultation on a listing regime for emerging and innovative companies and finalised the related Hong Kong Listing Rules and guidance letters.
From 30 April 2018, biotech companies that are pre-revenue are permitted to list under a new chapter (the Biotech Chapter) in the Main Board Listing Rules (the Listing Rules).
This material is provided for general information only. It does not constitute legal or other professional advice.
Are you sure want to delete comment ?
Scan this QR Code to share this content